WuXi PharmaTech Announces Fourth-Quarter and Full-Year 20...( SHANGHAI March 25 Asia/ -- WuXi P...)

SHANGHAI, March 25 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading research and development outsourcing company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States, today announced its financial results for fourth-quarter and full-year 2008.

    (Logo:http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

    Highlights
    -- Total Company(1) Full-Year 2008 Net Revenues of $261.8 Million
       (Including $8.3 Million of Net Revenues from Discontinued Operations)
       and Adjusted EBITDA of $72.2 Million Achieve Company's Financial
       Guidance
    -- 74% Year-Over-Year Net Revenue Growth from Continuing Operations in
       Fourth Quarter of 2008, 33% Organic Net Revenue Growth for China-Based
       Businesses
    -- 87% Year-Over-Year Net Revenue Growth from Continuing Operations for
       Full-Year 2008, 45% Organic Net Revenue Growth for China-Based
       Businesses
    -- Fourth-Quarter and Full-Year 2008 Net Losses Reflect Non-Cash
       Impairment Charges Relating to Continuing and Discontinued AppTec
       Operations
    -- Construction Completed at Suzhou Toxicology Laboratory and Expanded
       Jinshan Manufacturing Plant
    -- Company Targets 2009 Net Revenues of $265-$275 Million, Including
       15-20% Net Revenue Growth in China-Based Laboratory Services
    -- Key 2009 Investments in Laboratory Services, Toxicology, and
       Manufacturing Services Expected to Drive Revenue Growth in 2010 and
       Beyond

Management Comment

"2008 was a year of extraordinary economic challenges, both in the worldwide economy and the healthcare industry," said Dr. Ge Li, Chairman and Chief Executive Of
'/>"/>